A real-world retrospective study of ALK-rearranged NSCLC patients receiving ICIs demonstrated a median PFS of 3.9 months in patients who received ICIs prior to ALK-TKI treatment, compared with a median PFS of 1.5 months in patients who received ICIs after ALK-TKI treatment (5). The gene discussed is ALK; the disease is non-small cell lung carcinoma.